Literature DB >> 19189194

Providers' experiences treating chronic pain among opioid-dependent drug users.

Karina M Berg1, Julia H Arnsten, Galit Sacajiu, Alison Karasz.   

Abstract

BACKGROUND: Successful management of chronic pain with opioid medications requires balancing opioid dependence and addiction with pain relief and restoration of function. Evaluating these risks and benefits is difficult among patients with chronic pain and pre-existing addiction, and the ambiguity is increased for patients on methadone maintenance therapy for opioid dependence. Providers treating both chronic pain and addiction routinely make diagnostic and therapeutic decisions, but decision-making strategies in this context have not been well described.
OBJECTIVE: Our objective was twofold. We sought first to explore providers' perceptions of ambiguity, and then to examine their strategies for making diagnostic and treatment decisions to manage chronic pain among patients on methadone maintenance therapy.
DESIGN: Qualitative semi-structured interviews. SETTING AND PARTICIPANTS: We interviewed health-care providers delivering integrated medical care and substance abuse treatment to patients in a methadone maintenance program.
RESULTS: Providers treating pain and co-morbid addiction described ambiguity in all diagnostic and therapeutic decisions. To cope with this inherent ambiguity, most providers adopted one of two decision-making frameworks, which determined clinical behavior. One framework prioritized addiction treatment by emphasizing the destructive consequences of abusing illicit drugs or prescription medications; the other prioritized pain management by focusing on the destructive consequences of untreated pain. Identification with a decision-making framework shaped providers' experiences, including their treatment goals, perceptions of treatment risks, pain management strategies, and tolerance of ambiguity. Adherence to one of these two frameworks led to wide variation in pain management practices, which created tension among providers.
CONCLUSIONS: Providers delivering integrated medical care and substance abuse treatment to patients in a methadone maintenance program found tremendous ambiguity in the management of chronic pain. Most providers adopted one of the two divergent heuristic frameworks we identified, which resulted in significant variations in pain management. To reduce variation and determine best practices, studies should examine clinically relevant endpoints, including pain, illicit drug use, prescription drug abuse, and functional status. Until then, providers managing chronic pain in patients with co-morbid addiction should attempt to reduce tension by acknowledging ambiguity and engaging in open discourse.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19189194      PMCID: PMC2659151          DOI: 10.1007/s11606-009-0908-x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  32 in total

1.  Physicians' reactions to uncertainty in patient care. A new measure and new insights.

Authors:  M S Gerrity; R F DeVellis; J A Earp
Journal:  Med Care       Date:  1990-08       Impact factor: 2.983

2.  Variations in methadone treatment practices. Results from a national study.

Authors:  T D'Aunno; T E Vaughn
Journal:  JAMA       Date:  1992-01-08       Impact factor: 56.272

3.  Pain management in the chemically dependent patient.

Authors:  R D Hicks
Journal:  Hawaii Med J       Date:  1989-11

Review 4.  Physician uncertainty and the art of persuasion.

Authors:  J A Rizzo
Journal:  Soc Sci Med       Date:  1993-12       Impact factor: 4.634

5.  The experience of chronic severe pain in patients undergoing methadone maintenance treatment.

Authors:  Alison Karasz; Leah Zallman; Karina Berg; Marc Gourevitch; Peter Selwyn; Julia H Arnsten; Julia Arnstein
Journal:  J Pain Symptom Manage       Date:  2004-11       Impact factor: 3.612

6.  Treatment needs associated with pain in substance use disorder patients: implications for concurrent treatment.

Authors:  Jodie A Trafton; Elizabeth M Oliva; Doyanne A Horst; Jared D Minkel; Keith Humphreys
Journal:  Drug Alcohol Depend       Date:  2004-01-07       Impact factor: 4.492

7.  Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history.

Authors:  Edward Michna; Edgar L Ross; Wilfred L Hynes; Srdjan S Nedeljkovic; Sharonah Soumekh; David Janfaza; Diane Palombi; Robert N Jamison
Journal:  J Pain Symptom Manage       Date:  2004-09       Impact factor: 3.612

8.  Pain clinicians' rankings of aberrant drug-taking behaviors.

Authors:  Steven D Passik; Kenneth L Kirsh; Laurie Whitcomb; Pamela K Dickerson; Dale E Theobald
Journal:  J Pain Palliat Care Pharmacother       Date:  2002

9.  Variations in evidence-based clinical practices in nine United States Veterans Administration opioid agonist therapy clinics.

Authors:  Mark L Willenbring; Hildi J Hagedorn; Andrea C Postier; Marie Kenny
Journal:  Drug Alcohol Depend       Date:  2004-07-15       Impact factor: 4.492

10.  Diagnostic dilatation and curettage: is it used appropriately?

Authors:  A Coulter; A Klassen; I Z MacKenzie; K McPherson
Journal:  BMJ       Date:  1993-01-23
View more
  42 in total

1.  Providers' experiences treating chronic pain among opioid-dependent drug users.

Authors:  Darius A Rastegar
Journal:  J Gen Intern Med       Date:  2009-09       Impact factor: 5.128

2.  Characterizing pain and associated coping strategies in methadone and buprenorphine-maintained patients.

Authors:  Kelly E Dunn; Patrick H Finan; D Andrew Tompkins; Michael Fingerhood; Eric C Strain
Journal:  Drug Alcohol Depend       Date:  2015-10-19       Impact factor: 4.492

3.  Hospitals as a 'risk environment': an ethno-epidemiological study of voluntary and involuntary discharge from hospital against medical advice among people who inject drugs.

Authors:  Ryan McNeil; Will Small; Evan Wood; Thomas Kerr
Journal:  Soc Sci Med       Date:  2014-01-19       Impact factor: 4.634

4.  A pilot study assessing acceptability and feasibility of hatha yoga for chronic pain in people receiving opioid agonist therapy for opioid use disorder.

Authors:  Lisa A Uebelacker; Donnell Van Noppen; Geoffrey Tremont; Genie Bailey; Ana Abrantes; Michael Stein
Journal:  J Subst Abuse Treat       Date:  2019-07-24

Review 5.  Caring for patients with opioid use disorder in the hospital.

Authors:  Joseph H Donroe; Stephen R Holt; Jeanette M Tetrault
Journal:  CMAJ       Date:  2016-09-19       Impact factor: 8.262

6.  Psychiatric Disorders Among Patients Seeking Treatment for Co-Occurring Chronic Pain and Opioid Use Disorder.

Authors:  Declan T Barry; Christopher J Cutter; Mark Beitel; Robert D Kerns; Christopher Liong; Richard S Schottenfeld
Journal:  J Clin Psychiatry       Date:  2016-10       Impact factor: 4.384

7.  Primary care providers' views on chronic pain management among high-risk patients in safety net settings.

Authors:  Maya Vijayaraghavan; Joanne Penko; David Guzman; Christine Miaskowski; Margot B Kushel
Journal:  Pain Med       Date:  2012-07-30       Impact factor: 3.750

8.  Pain and associated substance use among opioid dependent individuals seeking office-based treatment with buprenorphine-naloxone: a needs assessment study.

Authors:  Declan T Barry; Jonathan D Savant; Mark Beitel; Christopher J Cutter; Brent A Moore; Richard S Schottenfeld; David A Fiellin
Journal:  Am J Addict       Date:  2013 May-Jun

9.  Characteristics of methadone maintenance treatment patients prescribed opioid analgesics.

Authors:  Matthew C Glenn; Nancy L Sohler; Joanna L Starrels; Jeronimo Maradiaga; John J Jost; Julia H Arnsten; Chinazo O Cunningham
Journal:  Subst Abus       Date:  2016-01-05       Impact factor: 3.716

10.  Use of conventional, complementary, and alternative treatments for pain among individuals seeking primary care treatment with buprenorphine-naloxone.

Authors:  Declan T Barry; Jonathan D Savant; Mark Beitel; Christopher J Cutter; Brent A Moore; Richard S Schottenfeld; David A Fiellin
Journal:  J Addict Med       Date:  2012-12       Impact factor: 3.702

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.